Patients with FPLD develop metabolic abnormalities including hypertriglyceridemia, insulin resistance, and diabetes mellitus, which are difficult to manage with conventional therapies including fibrates, statins, and insulin [67]. The gene discussed is INS; the disease is Insulin resistance.